Literature DB >> 33405390

Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site.

Xinrong Li1, Yan Shao2, Liqiang Sheng1, Junquan Zhu1, Zeming Wang1, Kaibo Guo3, Leitao Sun3,4.   

Abstract

BACKGROUND: Metastatic adenocarcinoma of unknown primary site (MACUP) is the most common cancer of unknown primary site, and shows worse prognosis. Prediction of its tumor site origin attracts a growing attention. However, the site determined by gene expression profiling does not have a significant impact on the survival. Some other special method might need to be found out.
METHODS: We reviewed 1011 MACUP patients diagnosed by pathological examination and immunohistochemistry based on the Surveillance, Epidemiology, and End Results (SEER) database during 2010-2016. Kaplan-Meier curves and Cox proportional hazard model were analyzed to compare the survival. Logistic regression models and relevant nomograms were performed to predicting the probability of the primary site which including digestive system, respiratory system, and female breast. The validation and clinical utility of models were measured with relevant statistical approaches.
RESULTS: About 324 (32.1%), 299 (29.6%), and 203 (20.1%) of MACUP patients were identified as the primary sites of digestive system, respiratory system, and female breast, respectively. Patients derived from digestive system and respiratory system showed poorer survival than these with other sites. Digestive system was significantly associated with liver (Odds ratio =13.21 [95% confidence interval =8.48-21.02]) or lung (2.36 [1.40-3.97]) metastasis, while respiratory system was linked to brain (11.68 [6.68-21.26]) or lymph node (3.39 [2.26-5.13]) metastasis. Patients identified as female breast were prone to occur bone metastasis (5.85 [3.68-9.45]). Logistic regression nomograms were developed to help clinicians intuitively predict the probabilities of tumor site origin with 0.867, 0.824, and 0.753 of the C-index, respectively. Decision curve analysis and clinical impact curves both revealed the clinical effectiveness.
CONCLUSIONS: We profiled different tumor site origin of MACUP patients and established prediction models. These features might be significant for clinicians to improve the probabilities of predicting the primary sites, and to decide subsequent treatment strategy.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  SEER; cancer of unknown primary site; metastatic adenocarcinoma; nomogram; predictors

Mesh:

Substances:

Year:  2021        PMID: 33405390      PMCID: PMC7897950          DOI: 10.1002/cam4.3684

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  21 in total

Review 1.  Nomograms in oncology: more than meets the eye.

Authors:  Vinod P Balachandran; Mithat Gonen; J Joshua Smith; Ronald P DeMatteo
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

Review 2.  New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?

Authors:  Elie Rassy; Pauline Parent; Felix Lefort; Stergios Boussios; Giulia Baciarello; Nicholas Pavlidis
Journal:  Crit Rev Oncol Hematol       Date:  2020-01-23       Impact factor: 6.312

3.  Survival in cancer of unknown primary site: population-based analysis by site and histology.

Authors:  K Hemminki; M Bevier; A Hemminki; J Sundquist
Journal:  Ann Oncol       Date:  2011-11-24       Impact factor: 32.976

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

5.  Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

Authors:  Hidetoshi Hayashi; Takayasu Kurata; Yuichi Takiguchi; Makoto Arai; Koji Takeda; Kohei Akiyoshi; Koji Matsumoto; Takuma Onoe; Hirofumi Mukai; Nobuaki Matsubara; Hironobu Minami; Masanori Toyoda; Yusuke Onozawa; Akira Ono; Yoshihiko Fujita; Kazuko Sakai; Yasuhiro Koh; Ayano Takeuchi; Yasuo Ohashi; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  J Clin Oncol       Date:  2019-01-17       Impact factor: 44.544

Review 6.  Cancer of unknown primary site.

Authors:  Nicholas Pavlidis; George Pentheroudakis
Journal:  Lancet       Date:  2012-03-12       Impact factor: 79.321

7.  Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012.

Authors:  C Schroten-Loef; R H A Verhoeven; I H J T de Hingh; A J van de Wouw; H W M van Laarhoven; V E P P Lemmens
Journal:  Eur J Cancer       Date:  2018-07-20       Impact factor: 9.162

Review 8.  Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors.

Authors:  F Anthony Greco; Nicholas Pavlidis
Journal:  Semin Oncol       Date:  2009-02       Impact factor: 4.929

Review 9.  Carcinoma of unknown primary (CUP).

Authors:  Nicholas Pavlidis; Karim Fizazi
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-01       Impact factor: 6.312

10.  Risk factors and predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer.

Authors:  Kaibo Guo; Yuqian Feng; Li Yuan; Harpreet S Wasan; Leitao Sun; Minhe Shen; Shanming Ruan
Journal:  Cancer Med       Date:  2020-05-29       Impact factor: 4.452

View more
  2 in total

1.  Laparoscopic Surgery for a Patient With Multiple Liver Metastases of Unknown Origin Concomitant With Gallbladder Tumor.

Authors:  Yoshihiro Hara; Kensuke Yamamura; Kazuki Matsumura; Eri Oda; Shinichi Akahoshi; Hideaki Yuki; Jun Tomiguchi; Toshihiko Motohara; Hideaki Miyamoto; Yoshihiko Komohara; Toru Beppu
Journal:  In Vivo       Date:  2021 Sep-Oct       Impact factor: 2.406

2.  Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site.

Authors:  Xinrong Li; Yan Shao; Liqiang Sheng; Junquan Zhu; Zeming Wang; Kaibo Guo; Leitao Sun
Journal:  Cancer Med       Date:  2021-01-06       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.